ClinicalTrials.gg
CompletedNCT01322282Updated Jul 10, 2012

To Test Bioequivalence Between Two Tablet Formulations in the Treatment of Allergy

A Phase 1 interventional study of Cetirizine and Cetirizine in Allergy, sponsored by McNeil AB. Completed at 1 site in Canada. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-07-10.

Sponsored by McNeil AB (formerly part of Johnson & Johnson) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 86 studies in Hypersensitivity with a site in Canada — 8 open to participants now, 12 under way, 1 of them phase 3. Hypersensitivity · Canada.

Enrollment
51st of 71
36 · median 64
Started
2011
with 3 others
Phase 1
10 of 86
1 open now
Registered
29th of 86
by date

Among the 86 studies in Hypersensitivity with a site in Canada, this one is the 51st largest by enrollment of the 71 interventional ones that give a count, is one of 4 that started in 2011, is one of 10 in phase 1, and was the 29th registered.

Hypersensitivity

1,058 studies on the registry are indexed under Hypersensitivity; 150 are open to participants now.

Browse Hypersensitivity studies →

Open to participants now

8 of the 86 studies in Hypersensitivity with a site in Canada are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 101 Hypersensitivity studies recruiting now, 37 (37%) set no upper age limit and 52 (51%) stop at 75 or younger; 56 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies in Hypersensitivity with a site in Canada, or all of them as a file.
02

Study summary

This study is designed to assess bioequivalence between two products used for treatment of allergy.

Read the detailed description

This study is designed to evaluate if a test formulation of cetirizine 10 mg orodispersible tablet (ODT) taken with and without water is bioequivalent to a marketed reference formulation of cetirizine 10 mg tablet (Benadryl One A Day, McNeil Products Ltd, UK) taken with water. This study will also evaluate the tolerability of test and reference formulations.

03

Conditions studied

  • Allergy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects
  • Volunteers aged of at least 18 years but not older than 55 years
  • Subjects will have a (BMI) greater than or equal to 18.50 and below 30.00 kg/m2
  • Non- or ex-smokers; an ex-smoker being defined as someone who completely stopped smoking for at least 12 months before day 1 of this study
  • Clinical laboratory values within the laboratory's stated normal range; if not within this range, they must be without any clinical significance
  • Have no diseases captured in the medical history or evidence of clinically significant findings on physical examination and/or clinical laboratory evaluations (hematology, biochemistry, and urinalysis)
  • Has signed and dated the document, indicating that the subject has been informed of all pertinent aspects of the study
  • Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures

Exclusion criteria

Exclusion Criteria:

  • Seated pulse rate below 45 bpm or higher than 90 bpm at screening
  • Seated blood pressure below 90/60 mmHg or higher than 140/90 mmHg at screening
  • Relationship to persons involved directly with the conduct of the study (i.e., principal investigator; sub-investigators; study coordinators; other study personnel; employees or contractors of the sponsor or Johnson \& Johnson subsidiaries; and the families of each)
  • Presence of any tongue piercings
  • Presence of braces
  • Females who are pregnant or are lactating
  • Females of or males with a female partner of childbearing potential who refuse to use an acceptable regimen throughout the entire duration of the study
  • Females who are pregnant according to a positive serum pregnancy test
  • Any medical history or condition, or use of any drug or medication, that the investigator determines could compromise subject safety or the evaluation of results.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Investigator)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    ODT with Water

    Experimental Cetirizine 10 mg Orodispersible Tablet (ODT) taken with 240 mL of water

    Drug: Cetirizine

  • Experimental
    ODT Without Water

    Experimental Cetirizine 10 mg Orodispersible Tablet (ODT) taken without 240 mL of water

    Drug: Cetirizine

  • Active comparator
    FCT with Water

    Marketed Cetirizine 10 mg Film-Coated Tablet (FCT) taken with 240 mL of water

    Drug: Cetirizine

Interventions

  • A single 10 mg dose of an experimental Cetirizine Orodispersible Tablet (ODT), with a 7-day washout period between visits

    Also known as: Not yet marketed

  • A single 10 mg dose of a marketed Cetirizine Film-Coated Tablet (FCT), with a 7-day washout period between visits

    Also known as: Benadryl One A Day 10 mg Film-Coated Tablet

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration

    Maximum Observed Plasma Concentration (Cmax), which is the maximum (peak) concentration (amount of drug) measurable in blood plasma after a dose is administered, measured in nanograms/milliliter (ng/mL)

    Time frame: During 32 hours post-dose

  2. Bioavailability [AUC(0-t)]

    Bioavailability \[AUC(0-t)\] is a measure of how much of the drug reaches the person's bloodstream within a given period of time for the body to use. The extent of product bioavailability is estimated by the area under the blood concentration vs time curve. The Area Under the Curve (AUC) is calculated by plotting the drug's blood levels on a graph at different times during the set period. The area under this curve reflects the amount of drug exposure in the set time period, calculated as hour \* nanograms (ng) per milliliter (mL).

    Time frame: During 32 hours post-dose

  3. Bioavailability Extrapolated to Infinity [AUC (0-∞)]

    Bioavailability Extrapolated to Infinity \[AUC (0-∞)\] is a calculated measure of how much of the drug will ever reach the person's bloodstream for the body to use. AUC (0-∞) stands for the area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (forever). It is obtained from calculating AUC (0-t) plus AUC (t-∞).

    Time frame: 32 hours post-dose

Secondary outcomes

  1. Time of Maximum Concentration

    The time at which maximum concentration is reached (Tmax)

    Time frame: During 32 hours post-dose

  2. Terminal Elimination Rate Constant

    The Terminal Elimination Rate Constant (Lamda z) is the time required to eliminate half the administered dose

    Time frame: During 32 hours post-dose

  3. Terminal Phase Plasma Half-Life

    Terminal phase plasma half-life (t ½) is the time required to divide the plasma concentration by two after reaching pseudo-equilibrium, rather than the time required to eliminate half the administered dose.

    Time frame: During 32 hours post-dose

  4. Area under the Curve to the Tmax of the Reference Products

    Area under the plasma concentration versus time curve to the time of the maximum concentration of the reference products (AUCReftmax)

    Time frame: During 32 hours post-dose

  5. Relative percentage of AUCT with respect to AUC∞ (AUCT/∞)

    AUCT is the area under the plasma concentration verses time curve from start of drug administration until the time of the last measurable plasma concentration. AUC∞ is the area under the plasma concentration versus time curve from start of drug administration until extrapolated infinite time. AUCT/ AUC∞ is an inversed measure of how large the extrapolated area under the curve is.

    Time frame: During 32 hours post-dose

  6. Mean Residence Time

    The average amount of time a particle (e.g., a drug substance molecule) remains in a compartment or system.

    Time frame: During 32 hours post-dose

07

Study locations

1 site
  • Algorithme Pharma Inc.
    Mount-Royal, Quebec H3P 3P1, Canada
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of Mar 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2011
First posted
Mar 24, 2011
Start
Feb 2011
Primary completionActual
Mar 2011
CompletionActual
Mar 2011
Last update
Jul 10, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01322282
Lead sponsor
McNeil AB
Responsible party
Sponsor
First posted
Mar 24, 2011
Start date
Feb 2011
Primary completion
Mar 2011
Completion
Mar 2011
Last update
Jul 10, 2012

Study contacts

Elisabeth Kruse, PhD
study director · McNeil AB

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cetirizine

Start the discussion